<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700800</url>
  </required_header>
  <id_info>
    <org_study_id>20-003294</org_study_id>
    <secondary_id>R01DK123441</secondary_id>
    <nct_id>NCT04700800</nct_id>
  </id_info>
  <brief_title>Regulation of Muscle Protein Phenotype in Humans With Obesity</brief_title>
  <official_title>Regulation of Muscle Protein Phenotype in Humans With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maintenance of protein homeostasis is impaired in skeletal muscle of humans with obesity. A&#xD;
      hallmark of this defect is distorted expression of isoforms of the myosin heavy chain (MHC)&#xD;
      protein, and this defect is linked to obesity-associated adverse health outcomes. By&#xD;
      employing exercise and increase in plasma amino acids as investigational tools the&#xD;
      investigators intend to modulate the metabolism of muscle MHC isoforms in order to unravel&#xD;
      the biological mechanisms that sustain distorted MHC protein metabolism in muscle of humans&#xD;
      with obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Distorted expression of isoforms of the skeletal muscle myosin heavy chain (MHC) protein is a&#xD;
      hallmark of altered protein metabolism in muscle of humans with obesity. The most striking&#xD;
      feature of this, is a characteristic reduction in the content of the slow MHC-I isoform,&#xD;
      which is responsible for determining the content of Type I muscle fibers. These fibers are&#xD;
      characterized by increased capacity for glucose uptake, and in contrast to Type II fibers,&#xD;
      maintain sensitivity to fuel metabolism within the adverse metabolic environment of obesity.&#xD;
      Increased content of Type I fibers in skeletal muscle, and thus favorable metabolic effects&#xD;
      in muscle, require increased expression of MHC-I in muscle. Importantly, the slow MHC-I gene&#xD;
      drives the molecular mechanisms that determine the overall MHC protein metabolism and fiber&#xD;
      type phenotype in skeletal muscle. The project seeks to determine the underlying biology that&#xD;
      sustains distorted MHC protein metabolism in skeletal muscle of humans with obesity.&#xD;
&#xD;
      The investigators evaluate protein metabolism in skeletal muscle of humans with obesity and&#xD;
      lean controls, and focus specifically on that of MHC isoforms. The investigators determine&#xD;
      gene expression of the MHC isoforms and associated molecular factors implicated in activating&#xD;
      Type I muscle fiber programming. Acute aerobic exercise and increase in plasma amino acids&#xD;
      are employed as experimental tools to target biological processes of transcription and&#xD;
      translation related to MHC genes expression in skeletal muscle. The overall findings will&#xD;
      provide an understanding of mechanisms responsible for unfavorable MHC proteome and fiber&#xD;
      type phenotype in skeletal muscle of humans with obesity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Protein Synthesis</measure>
    <time_frame>9 Hours on 2 separate days one month apart</time_frame>
    <description>Change from baseline in the synthesis rates of overall protein, overall mitochondrial protein, and myosin heavy chain (MHC) isoforms (MHC-I, MHC-IIa, and MHC-IIx) in skeletal muscle will be evaluated in response to the following interventions:&#xD;
exercise+amino acid infusion&#xD;
amino acid infusion&#xD;
exercise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Eukaryotic initiation factor 4F (eIF4F)</measure>
    <time_frame>9 Hours on 2 separate days one month apart</time_frame>
    <description>Change from baseline in the formation of the active eIF4F complex in skeletal muscle will be evaluated in response to the following interventions:&#xD;
exercise+amino acid infusion&#xD;
amino acid infusion&#xD;
exercise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mRNA</measure>
    <time_frame>9 Hours on 2 separate days one month apart</time_frame>
    <description>Change from baseline in mRNA content of MHC-I, MHC-IIa, and MHC-IIx in skeletal muscle will be evaluated in response to the following interventions:&#xD;
exercise+amino acid infusion&#xD;
amino acid infusion&#xD;
exercise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Protein breakdown</measure>
    <time_frame>9 Hours on 2 separate days one month apart</time_frame>
    <description>Change from baseline in the breakdown rates of overall protein and myosin heavy chain (MHC) isoforms (MHC-I, MHC-IIa, and MHC-IIx) in skeletal muscle will be evaluated in response to the following interventions:&#xD;
exercise+amino acid infusion&#xD;
amino acid infusion&#xD;
exercise</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Exercise, Infusion of Amino Acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise followed by infusion of amino acids, or infusion of amino acids alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exercise with no infusion of amino acids</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake</description>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_label>Exercise, Infusion of Amino Acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infusion of Amino Acids</intervention_name>
    <description>Intravenous infusion of mixture of amino acids</description>
    <arm_group_label>Exercise, Infusion of Amino Acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ability to sign informed consent form&#xD;
&#xD;
          -  body mass index (BMI), 18-25 kg/m2 (lean subjects), 35-45 kg/m2 (subjects with&#xD;
             obesity)&#xD;
&#xD;
          -  insulin sensitivity (Matsuda insulin sensitivity index: lean &gt; 7, subjects with&#xD;
             obesity &lt; 4).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prescription or over-the-counter medication&#xD;
&#xD;
          -  supplements known to affect protein metabolism (i.e., amino acids, protein, omega-3&#xD;
             fatty acids)&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  acute illness&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  uncontrolled metabolic disease, including renal disease&#xD;
&#xD;
          -  heart disease related to atrial fibrillation, history of syncope, limiting or unstable&#xD;
             angina, congestive heart failure or ECG documented abnormalities such as &gt;0.2 mV&#xD;
             horizontal or downsloping ST-segment depression, or frequent arrhythmias (&gt;10&#xD;
             premature ventricular contractions/min)&#xD;
&#xD;
          -  low hemoglobin or hematocrit&#xD;
&#xD;
          -  use of anabolic steroids or corticosteroids (within 3 months)&#xD;
&#xD;
          -  not classified as inactive/sedentary based on the Stanford Brief Activity Survey and&#xD;
             accelerometry data&#xD;
&#xD;
          -  participation in a weight-loss regimen&#xD;
&#xD;
          -  extreme dietary practices (i.e., vegan, vegetarian)&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  gastro-intestinal surgery&#xD;
&#xD;
          -  any other condition or event considered exclusionary by the PI and the study&#xD;
             physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori R Roust, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos S Katsanos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christos S Katsanos</last_name>
    <phone>480-301-6015</phone>
    <email>christos.katsanos@asu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lori R Roust</last_name>
    <email>roust.lori@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Lori R. Roust</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

